Monimus Capital Management LP Takes Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Monimus Capital Management LP bought a new stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 47,100 shares of the company’s stock, valued at approximately $182,000. Monimus Capital Management LP owned about 0.07% of Larimar Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in Larimar Therapeutics by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock worth $143,000 after buying an additional 3,425 shares during the last quarter. Franklin Resources Inc. increased its holdings in Larimar Therapeutics by 21.9% during the third quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after buying an additional 3,549 shares during the last quarter. Quarry LP increased its holdings in Larimar Therapeutics by 50.0% during the third quarter. Quarry LP now owns 12,000 shares of the company’s stock worth $79,000 after buying an additional 4,000 shares during the last quarter. SG Americas Securities LLC increased its holdings in Larimar Therapeutics by 35.1% during the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock worth $75,000 after buying an additional 5,042 shares during the last quarter. Finally, Quest Partners LLC increased its holdings in Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock worth $60,000 after buying an additional 5,796 shares during the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Stock Down 0.8 %

NASDAQ LRMR opened at $2.59 on Friday. Larimar Therapeutics, Inc. has a 52 week low of $2.52 and a 52 week high of $11.20. The firm has a market capitalization of $165.26 million, a P/E ratio of -2.25 and a beta of 0.99. The company has a 50-day moving average price of $3.31 and a 200-day moving average price of $5.50.

Analyst Ratings Changes

Several research firms have recently weighed in on LRMR. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Larimar Therapeutics in a research note on Friday, January 24th. Truist Financial began coverage on shares of Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a “buy” rating and a $18.00 target price for the company. Finally, William Blair reiterated an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 19th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $20.13.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.